Company Overview - Prasis (Shanghai) Pharmaceutical Technology Development Co., Ltd. is a data-driven clinical research service provider focused on patient-centered approaches, creating a comprehensive project management system for clinical trials [1] - As of September 30, 2024, the company has undertaken over 3,400 SMO projects, with 2,011 currently in execution [2] - The company employs 4,692 staff and has served over 940 clinical trial institutions, covering more than 1,300 institutions across over 190 cities in China [2] Financial Performance - In the first half of 2024, the company signed new contracts worth 429 million CNY (approximately 62 million USD) [2] - The company emphasizes maintaining order quality and sustainable long-term development strategies despite external market challenges [2] Client Structure - The client base primarily consists of multinational pharmaceutical companies, domestic innovative drug companies, and CROs, with a focus on high-value innovative drug SMO projects [2] - The company collaborates with all of the top 10 global pharmaceutical companies as of 2023, showcasing its capability in providing high-quality SMO services [2] Recruitment and Workforce Management - Recruitment plans are determined based on project needs, new contracts, labor utilization rates, and institutional requirements [3] Technological Advancements - The company is focused on enhancing project execution efficiency through digitalization and new technologies, including AI integration [4] - Internal systems have been upgraded to improve work efficiency and project execution quality [4] M&A Strategy - The company maintains an open attitude towards mergers and acquisitions, considering overall strategy, business development, and valuation cautiously [4]